Back to top
more

Structure Therapeutics Inc. Sponsored ADR (GPCR)

(Delayed Data from NSDQ)

$16.68 USD

16.68
948,732

-0.10 (-0.60%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $16.66 -0.02 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study

by Zacks Equity Research

Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.

Ahan Chakraborty headshot

NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback

by Ahan Chakraborty

Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.

Zacks Equity Research

Best Momentum Stocks to Buy for October 23rd

by Zacks Equity Research

GPCR, RUSHA and NTRA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 23, 2024.

Zacks Equity Research

Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at an 115.8% upside potential for Structure Therapeutics Inc. Sponsored ADR (GPCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Kinjel Shah headshot

NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise

by Kinjel Shah

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.

Zacks Equity Research

Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy

by Zacks Equity Research

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.

Zacks Equity Research

What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?

by Zacks Equity Research

Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.

Zacks Equity Research

Structure Therapeutics (GPCR) Rallying on Obesity Drug Data

by Zacks Equity Research

Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.

Zacks Equity Research

Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why

by Zacks Equity Research

Structure Therapeutics (GPCR) rises 9% on encouraging initial data from the early-stage study of its pipeline candidate, GSBR-1290, in healthy overweight or obese individuals.

Sanghamitra Saha headshot

IPO Round Up of First Half of 2023

by Sanghamitra Saha

Normally, IPO activity gains momentum in the second quarter and peaks in June. This year was no exception.